Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-117 in healthy subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sequence A (RT) | Experimental | Period 1: Reference (AD-117A), Period 2: Test (AD-117) |
|
| Sequence B (TR) | Experimental | Period 1: Test (AD-117), Period 2: Reference (AD-117A) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AD-117 | Drug | AD-117 1Tab., Per Oral |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum concentration of drug in plasma (Cmax) | Cmax of AD-117 | pre-dose (0hour) to 72hours |
| Area under the plasma concentration-time curve during dosing interval (AUCt) | AUCt of AD-117 | pre-dose (0hour) to 72hours |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Dasom Kim | Contact | +82-31-891-5572 | dskim@addpharma.co.kr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| H Plus Yangji Hospital | Seoul | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| AD-117A |
| Drug |
AD-117A 1Tab., Per Oral |
|